Alexion's asfotase alfa meets primary endpoint in hypophosphatasia study


Researchers have presented data from a Phase 2 study of Alexion Pharmaceuticals' (ALXN) targeted enzyme replacement therapy asfotase alfa in children and infants with hypophosphatasia.

The study met its primary endpoint of improving skeletal mineralization from baseline.

Improvement was observed as soon as 12 weeks and continued at 48 weeks, with 93% of those treated surviving the first four years of treatment.

The drug has a Breakthrough Therapy designation. (PR)

From other sites
Comments (1)
  • Chris DeMuth Jr.
    , contributor
    Comments (10595) | Send Message
     
    Great news for Rangeley Capital and all of our fellow ALXN shareholders.
    22 Sep 2013, 05:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs